Profile for Montenegro Patent: 00131

US Patent Family Members and Approved Drugs for Montenegro Patent: 00131

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Dec 1, 2026	Janssen Therap	SIRTURO	bedaquiline fumarate

Key insights for pharmaceutical patentability - Montenegro patent ME00131

Last updated: April 23, 2026

What is the scope and claim position of Montenegro drug patent ME00131, and how does it sit in the wider landscape?

What does Montenegro drug patent ME00131 cover (scope and claim center)?

No substantive record of Montenegro drug patent “ME00131” is available in the public patent-retrieval sources required to extract claim language, priority/filing dates, assignee, jurisdictional family members, and legal status. Without verifiable bibliographic and legal-document data for ME00131, a complete and accurate scope-and-claims analysis cannot be produced.

What are the claim elements and legal boundaries for ME00131?

A claim-by-claim breakdown requires the actual claims text (or at minimum the claim set and claim numbering as published) from the Montenegro patent publication and/or its authoritative family equivalents. No claim set for ME00131 is available from sources needed to produce a precise analysis.

What is the patent landscape around ME00131 (family, overlapping IP, and exclusion risk)?

Landscape mapping requires:

• the same invention family (priority chain) for ME00131
• identification of compound, composition, formulation, dosing regimen, use, and process counterparts
• current status (in force, expired, lapsed, withdrawn, or invalidated)
• cross-jurisdiction overlap against reference product and key generics/biosimilars in the Montenegro market

For ME00131, those inputs are not available in the sources required to ensure completeness and correctness. As a result, a landscape that is actionable for R&D and investment decisions cannot be generated.

---

Key Takeaways

• No verifiable patent-document content (bibliography, claims, status, or family mapping) for ME00131 is available from the required public sources, so scope and claims cannot be analyzed to a decision-grade standard.
• No landscape overlay (family overlap, expiry timing, or freedom-to-operate risk) can be produced without the authoritative ME00131 record and its claim set.

---

FAQs

1) Does ME00131 have compound claims, use claims, or formulation claims?
Not determinable without the ME00131 claims text and publication record.

2) What is ME00131’s expiration date in Montenegro?
Not determinable without ME00131 legal status and term calculation inputs.

3) Is ME00131 part of a larger global patent family?
Not determinable without the priority chain and publication identifiers.

4) Are there reported invalidations, oppositions, or restrictions affecting ME00131?
Not determinable without official status and legal-history documents for ME00131.

5) What generics or biosimilars could be impacted by ME00131?
Not determinable without market authorization linkages and ME00131 family/claim scope.

---

References

[1] (No citable sources available for ME00131 scope/claims in the required document repositories.)